Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience

Conclusions In this population-based analysis, the combination of bevacizumab and platinum–based chemotherapy as first-line therapy for metastatic, recurrent, or persistent cervical carcinoma was safely delivered and had outcomes comparable to results from the GOG 240 phase III trial.
Source: International Journal of Gynecological Cancer - Category: Cancer & Oncology Tags: Cervical Cancer Source Type: research